Novartis investors intensify pressure on the company's M&A strategy after a string of trial failures, Michelle Carnahan ...

Carl Valenstein is a partner with Morgan Lewis and co-leads the firm’s Environmental, Social, and Governance (ESG) & Sustainability team. Shabeena Sharak, a summer associate with the firm, contributed ...

Novartis investors are placing increased pressure on Novartis’ dealmaking strategy after facing setbacks to drugs acquired ...

The health care industry has invested heavily in point solutions ($100 billion). We have one tool for scheduling, another for ...

This June, ten of the life sciences industry’s most respected board members came to New York for Accenture’s second annual Life Sciences Board Forum for something this industr ...

GLP-1 medications might be most well-known as weight-loss options, but they were originally developed as a treatment for type 2 diabetes. For many patients, the drugs remain a highly effective ...